Every 10-Q that Cryo-Cell International Inc. (CCEL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CCEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CCEL filings page.
Cryo-Cell International (CCEL) filed its quarterly report, showing stable operations with softer topline. Revenue for the quarter ended August 31, 2025 was $7.83 million versus $8.07 million a year ago, as public banking and product sales remained small. Operating income improved to $1.90 million from $1.39 million on lower cost of sales and SG&A. Net income was $0.75 million ($0.09 diluted EPS) compared with $1.05 million ($0.13) last year.
For the nine months, revenue was $23.72 million versus $23.96 million; net income was $1.39 million ($0.17 diluted EPS) versus $2.26 million ($0.27). Interest expense weighed on results at $0.54 million in the quarter and $1.58 million year-to-date.
Deferred revenue tied to long-term storage contracts rose to $59.58 million ($9.74 million current), supporting future revenue recognition. Cash was $265,207 with $2.96 million in marketable securities. The company reported a stockholders’ deficit of $14.83 million driven by deferred revenue accounting and treasury stock. Debt included a $3.20 million line of credit and $8.39 million term note. As of October 15, 2025, 8,055,150 common shares were outstanding.